Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

Recruiting now · Not applicable

Conditions studied: Severe Tricuspid Regurgitation

In brief

This clinical trial evaluates the safety and effectiveness of the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in symptomatic patients with severe or greater tricuspid regurgitation.

Key facts

Study ID

NCT07321899

Run by

Medtronic Cardiovascular

People needed

1186

Starts

2026-08-01

Expected to finish

2041-04-01

Last updated by the study team

2026-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years at the time of consent.
• Severe symptomatic tricuspid regurgitation (TR) despite optimal medical therapy (OMT).
• Local site multidisciplinary heart team experienced in tricuspid valve therapies agrees that the subject is appropriate for TTVR.

You may not qualify if…

• Any tricuspid device currently in place.
• Anatomic contraindications.
• Need for emergent or urgent surgery.
• Left ventricular ejection fraction <25%.

Where it is running

• Abrazo Arizona Heart Hospital — Phoenix, Arizona, United States (enrolling)
• Los Robles Hospital & Medical Center — Thousand Oaks, California, United States (enrolling)
• Abbott Northwestern Hospital — Minneapolis, Minnesota, United States (enrolling)
• The Christ Hospital — Cincinnati, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.